statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	585
CN - Cina	167
SG - Singapore	136
GB - Regno Unito	113
IT - Italia	102
DE - Germania	85
BR - Brasile	45
SE - Svezia	40
RU - Federazione Russa	32
HK - Hong Kong	31
VN - Vietnam	31
FR - Francia	23
IN - India	22
FI - Finlandia	19
NL - Olanda	18
BD - Bangladesh	16
CA - Canada	14
IE - Irlanda	13
AU - Australia	12
ID - Indonesia	12
TR - Turchia	12
CI - Costa d'Avorio	10
AT - Austria	7
KR - Corea	7
BE - Belgio	6
JP - Giappone	6
PL - Polonia	6
PK - Pakistan	5
ZA - Sudafrica	5
AR - Argentina	4
CH - Svizzera	4
DK - Danimarca	4
ES - Italia	4
IQ - Iraq	4
MY - Malesia	3
PH - Filippine	3
BG - Bulgaria	2
CZ - Repubblica Ceca	2
DZ - Algeria	2
EC - Ecuador	2
EG - Egitto	2
IR - Iran	2
MX - Messico	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
CL - Cile	1
CO - Colombia	1
ET - Etiopia	1
HU - Ungheria	1
JO - Giordania	1
KG - Kirghizistan	1
LU - Lussemburgo	1
MA - Marocco	1
MK - Macedonia	1
MO - Macao, regione amministrativa speciale della Cina	1
MU - Mauritius	1
NO - Norvegia	1
PE - Perù	1
PS - Palestinian Territory	1
PT - Portogallo	1
SC - Seychelles	1
SI - Slovenia	1
SK - Slovacchia (Repubblica Slovacca)	1
Totale	1.640

Nome	#
Associazione tra calcificazione aortica addominale, patologia cardiovascolare e patologia ossea in una coorte di pazienti con infezione da HIV-1	290
Association between abdominal aortic calcifications, bone mineral density and vertebral fractures in a cohort of HIV-positive patients	271
The importance of patients’ case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease	212
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy : comment	212
Immunophenotype and function of CD38-expressing CD4+ and CD8+ T cells in HIV-infected patients undergoing suppressive combination antiretroviral therapy	196
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients	169
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment With Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients	164
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study	149
Long-term immune and epigenetic dysregulation following COVID-19	30
null	3
Totale	1.696

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	13	0	0	0	0	0	0	0	0	0	0	10	3
2021/2022	135	9	12	5	8	9	11	7	12	19	12	6	25
2022/2023	115	13	14	14	12	15	20	0	5	14	0	6	2
2023/2024	167	7	8	9	18	57	11	14	10	9	3	9	12
2024/2025	313	18	27	3	28	25	14	14	27	17	44	42	54
2025/2026	667	68	77	84	62	46	38	73	27	61	67	64	0
Totale													1.696

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca